Displaying 121 - 140 of 1406
FTC Sends 28 Warning Letters Regarding Agency’s Eyeglass Rule
FTC Challenges Hackensack Meridian Health, Inc.’s Proposed Acquisition of Competitor Englewood Healthcare Foundation
FTC Approves Otto Bock HealthCare North America, Inc.’s Application to Divest Assets It Gained through Acquisition of FIH Group Holdings, LLC
Statement of Commissioner Christine S. Wilson, Joined by Commissioner Noah Joshua Phillips, In the Matter of Methodist Le Bonheur Healthcare
FTC Sues to Block Proposed Acquisition of Two Memphis-Area Hospitals
Pfizer Inc. and Mylan N.V.; Analysis of Agreement Containing Consent Orders To Aid Public Comment
PrivacyCon 2021
Stryker and Wright Medical; Analysis of Consent Orders To Aid Public Comment
Statement of Commissioner Rohit Chopra in the Matter of Stryker and Wright Medical
FTC Requires Medical Device Companies Stryker Corp. and Wright Medical Group N.V. to Divest Assets to Preserve Competition
Statement of Commissioner Christine S. Wilson in the Matter of Pfizer Inc./Mylan N.V.
Dissenting Statement of Commissioner Rohit Chopra Joined by Commissioner Rebecca Kelly Slaughter in the Matter of Pfizer Inc./Mylan N.V.
Statement of Commissioner Rohit Chopra Regarding the Report to Congress on Protecting Older Consumers
FTC Requests Public Comment on Otto Bock HealthCare North America, Inc.’s Application to Approve Divestiture of Assets It Gained through Acquisition of FIH Group Holdings, LLC
ZyCal Bioceuticals Healthcare Company, Inc.
In February 2020, the FTC filed a complaint in federal district court against ZyCal Bioceuticals, a company that manufactured and sold the ingredient Cyplexinol to trade customers for use in making pain relief products for joint ailments, such as arthritis. Zycal also marketed a line of Cyplexinol-based pain relief products to chiropractors and directly to consumers under the brand name Ostinol. The same complaint includes allegations against another company, Excellent Marketing Results, Inc. (EMR), which was one of ZyCal's trade customers. EMR marketed a Cyplexinol-based formulation called StimTein via infomercials and online, and claimed it was clinically proven to stimulate cells to grow bone tissue and cartilage. EMR and its president agreed to a settlement that resolves charges against them in the FTC’s complaint, and prohibits them from making such health-related product claims unless they are supported by competent and reliable scientific evidence. In September 2020, the FTC announced it was returning more than $110,000 to consumers who bought EMR’s StimTein.
FTC Staff Submits Public Comment in Texas Opposing Certificate of Public Advantage Applications
FTC Staff Comment to Texas Health and Human Services Commission Regarding Certificate of Public Advantage Applications
FTC Staff Comment to Attorney General of Texas Concerning Certified Registered Nurse Anesthetists (CRNA) Regulations
FTC Comment to Texas Attorney General Raises Concerns about Likely Competitive Effect of Proposed Regulations Imposing Additional Supervisory Requirements on Texas Certified Nurse Anesthetists
Displaying 121 - 140 of 1406